64202 Federal Register / Vol. 79, No. 208 / Tuesday, October 28, 2014 / Notices 

withdrawn from sale for reasons of 

safety or effectiveness. 

Accordingly, the Agency will 

continue to list DIAMOX 

(acetazolamide) intravenous, 500 mg 

base/vial, and DIAMOX (acetazolamide) 

tablets, 125 mg and 250 mg, in the 

‘‘Discontinued Drug Product List’’ 

section of the Orange Book. The 

‘‘Discontinued Drug Product List’’ 

delineates, among other items, drug 

products that have been discontinued 

from marketing for reasons other than 

safety or effectiveness. FDA will not 

begin procedures to withdraw approval 

of ANDAs that refer to DIAMOX 

(acetazolamide) intravenous, 500 mg 

base/vial, and DIAMOX (acetazolamide) 

tablets, 125 mg and 250 mg. Additional 

ANDAs that refer to these products may 

also be approved by the Agency as long 

as they meet all other legal and 

regulatory requirements for the approval 

of ANDAs. If FDA determines that 

labeling for these drug products should 

be revised to meet current standards, the 

Agency will advise ANDA applicants to 

submit such labeling. 

Dated: October 21, 2014. 

Leslie Kux, 

Assistant Commissioner for Policy. 

[FR Doc. 2014–25534 Filed 10–27–14; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Submission for OMB Review; 30-Day 

Comment Request: Generic Clearance 

for Satisfaction Surveys of Customers 

(CSR) 

SUMMARY: Under the provisions of 

Section 3507(a)(l)(D) of the Paperwork 

Reduction Act of 1995, the National 

Institutes of Health (NIH) has submitted 

to the Office of Management and Budget 

(OMB) a request for review and 

approval of the information collection 

listed below. This proposed information 

collection was previously published in 

the Federal Register on August 21, 

2014, page 49523 and allowed 60 days 

for public comment. No public 

comments were received. The purpose 

of this notice is to allow an additional 

30 days for public comment. The Center 

for Scientific Review (CSR), National 

Institutes of Health, may not conduct or 

sponsor, and the respondent is not 

required to respond to, an information 

collection that has been extended, 

revised, or implemented on or after 

October 31, 2014, unless it displays a 

currently valid OMB control number. 

Direct Comments to OMB: Written 

comments and/or suggestions regarding 

the item(s) contained in this notice, 

especially regarding the estimated 

public burden and associated response 

time, should be directed to the: Office 

of Management and Budget, Office of 

Regulatory Affairs, OIRA_submission@

omb.eop.gov or by fax to 202–395–6974, 

Attention: NIH Desk Officer. 

DATES: Comment Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 30 days of the date of 

this publication. 

FOR FURTHER INFORMATION CONTACT: To 

obtain a copy of the data collection 

plans and instruments, submit 

comments in writing, or request more 

information on the proposed project 

contact: Dr. Mary Ann Guadagno, 

Project Clearance Liaison, Center for 

Scientific Review, NIH, Room 3182, 

6701 Rockledge Drive, Bethesda, MD 

20892, or call non-toll-free number (301) 

435–1251 or Email your request, 

including your address to: guadagma@

csr.nih.gov. Formal requests for 

additional plans and instruments must 

be requested in writing. 

Proposed Collection: Generic 

Clearance for Satisfaction Surveys of 

Customers (CSR), 0925–0474— 

extension, Center for Scientific Review 

(CSR), National Institutes of Health 

(NIH). 

Need and Use of Information 

Collection: The information collected in 

these surveys will be used by the Center 

for Scientific Review management and 

personnel: (1) To assess the quality of 

the modified operations and processes 

now used by CSR to review grant 

applications; (2) To assess the quality of 

service provided by CSR to our 

customers; (3) To enable identification 

of the most promising biomedical 

research that will have the greatest 

impact on improving public health by 

using a peer review process that is fair 

unbiased from outside influence, timely, 

and (4) To develop new modes of 

operation based on customer need and 

customer feedback about the efficacy of 

implemented modifications. These 

surveys will almost certainly lead to 

quality improvement activities to 

enhance and/or streamline CSR’s 

operations. The major mechanism by 

which CSR will request input is through 

surveys. The major initiatives ongoing at 

the present time include: Evaluation of 

the peer review process, surveys of new 

and early stage investigators, 

satisfaction with study section meetings 

using alternative review platforms, 

quick feedback for peer review, 

satisfaction with new reviewer 

orientation sessions, teleworker space 

needs, improving study section 

alignment to ensure the best reviews, 

and others. Surveys will be collected via 

Internet or in focus groups. Information 

gathered from these surveys will be 

presented to, and used directly by, CSR 

management to enhance the operations, 

processes, organization of, and services 

provided by the Center. 

OMB approval is requested for 3 

years. There are no costs to respondents 

other than their time. The total 

estimated annualized burden hours are 

4323. 

ESTIMATED ANNUALIZED BURDEN HOURS

Form name Type of respondent Number of 

respondents 

Number of 

responses 

per 

respondent 

Average 

burden per 

response 

(in hours) 

Total annual 

burden hour 

A ............... Adult scientific professionals (via Mail/Telephone/Internet) ...... 7925 1 30/60 3963 

B ............... Adult scientific professionals (via focus groups) ....................... 240 1 90/60 360 


asabaliauskas on DSK4SPTVN1PROD with NOTICES
Federal Register / Vol. 79, No. 208 / Tuesday, October 28, 2014 / Notices 64203 

Dated: October 20, 2014. 

Mary Ann Guadagno, 

Project Clearance Liaison, Center for 

Scientific Review, National Institutes of 

Health. 

[FR Doc. 2014–25601 Filed 10–27–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

President’s Cancer Panel. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: President’s Cancer 

Panel. 

Date: December 11, 2014. 

Time: 8:30 a.m. to 4:00 p.m. 

Agenda: Connected Health: Improving 

Patients’ Engagement and Activation for 

Cancer-Related Health. 

Place: Royal Sonesta Hotel Boston, 40 

Edwin Land Blvd., Cambridge, MA 02142. 

Contact Person: Abby B. Sandler, Ph.D., 

Executive Secretary, President’s Cancer 

Panel, Special Assistant to the Director, NCI 

Center for Cancer Research, 9000 Rockville 

Pike, Building 31, Room B2B37, MSC 2590, 

Bethesda, MD 20892–8349, (301) 451–9399, 

sandlera@mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: http://

deainfo.nci.nih.gov/advisory/pcp/index.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: October 22, 2014. 

Melanie J. Gray, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–25505 Filed 10–27–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Peer Review Meeting. 

Date: November 18–19, 2014. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: Doubletree by Hilton Bethesda— 

Washington, DC, 8120 Wisconsin Avenue, 

Bethesda, MD 20814, 301–664–7310, Fax: 

301–664–7317. 

Contact Person: Susana Mendez, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

DHHS/NIH/NIAID, 5601 Fishers Lane, MSC 

9823, Rockville, MD 20852, 240–669–5077, 

Fax: 301–480–2408, susana.mendez@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: October 22, 2014. 

David Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–25509 Filed 10–27–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel, NIAID Division of Allergy, 

Immunology and Transplantation: Statistical 

and Clinical Coordinating Center. 

Date: November 17, 2014. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 5601 

Fisher Lane, MSC 9823, Room 3F100, 

Rockville, MD 20852, (Telephone Conference 

Call). 

Contact Person: Paul A. Amstad, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institutes of Health/NIAID, 5601 

Fisher Lane, MSC 9823, Rockville, MD 

20852, 240–669–5067, PAmstad@

niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: October 22, 2014. 

David Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–25507 Filed 10–27–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 


asabaliauskas on DSK4SPTVN1PROD with NOTICES